TCMDMEDIUM SIGNALFINANCIAL10-K

TCMD delivered strong operational performance with 32% operating income growth and significantly increased share buybacks, while successfully reducing debt burden and inventory levels.

The company demonstrates improving operational efficiency with operating leverage driving income growth that outpaced revenue gains. The dramatic 657% increase in share buybacks signals management confidence and commitment to returning capital to shareholders, though the declining cash position warrants monitoring.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

TCMD showed strong financial momentum with revenue growing 12.5% to $329.5M and operating income surging 32% to $29.3M, demonstrating effective operational leverage. The company strengthened its balance sheet by reducing total liabilities 32% and optimizing inventory levels down 25%, while dramatically increasing shareholder returns through $26.6M in buybacks versus $3.5M prior year. Despite an 11.6% decline in cash to $83.4M due to the increased capital returns, the overall picture reflects a financially healthy company generating strong cash flows and efficiently deploying capital.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+657.2%
$3.5M$26.6M

Share repurchases increased 657.2% — management returning capital, signals confidence in intrinsic value.

Total Liabilities
Balance Sheet
-32.3%
$81.3M$55.0M

Liabilities reduced 32.3% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+32%
$22.2M$29.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
-24.9%
$18.7M$14.0M

Inventory reduced 24.9% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
+15.4%
$216.7M$250.1M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+12.5%
$293.0M$329.5M

Revenue growing 12.5% — solid top-line momentum, watch margins for quality of growth.

Net Income
P&L
+12.5%
$17.0M$19.1M

Net income grew 12.5% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-11.6%
$94.4M$83.4M

Cash decreased 11.6% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
- Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results.
Further, requirements to comply with new laws, regulations and guidance may have an adverse effect on our financial condition and results of operations.
- Our products are currently made available to authorized users of the Department of Veterans Affairs Federal Supply Schedule and if we were no longer eligible to sell our products through such channel, our business may be adversely affected.
For our respiratory therapy product, we have a durable medical equipment ( DME ) distribution model, through which we sell the AffloVest product to accredited DME providers, whose representatives gather and submit documentation for payer reimbursement, train patients on use of the device, and provide ongoing patient support.
For the year ended December 31, 2025, we generated revenue of $329.5 million and had net income of $19.1 million.
+7 more — sign up free →
REMOVED
You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the SEC that advise of the risks and factors that may affect our business.
Government Regulation, Compliance and Legal Risks - We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could be required to repay amounts previously received, and could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results.
For our respiratory therapy products, we have a durable medical equipment ( DME ) distribution model, utilizing mature comprehensive respiratory DME provider representatives to service patients.
We sell the AffloVest product to accredited DME providers, whose representatives gather and submit documentation for payer reimbursement, train patients on use of the device, and provide ongoing patient support.
For the year ended December 31, 2024, we generated revenue of $293.0 million and had net income of $17.0 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →